TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01085214

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: AZD6244 (Selumetinib), 75 mg was administered orally, twice a day, continuously for 28-day cycles
Study: NCT00789555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine hydrochloride 0.6% nasal spray (PATANASE)
Description: Two sprays in each nostril twice a day (morning and evening) for up to 12 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Olopatadine nasal spray vehicle, pH 3.7
Description: Two sprays in each nostril twice a day (morning and evening) for up to 12 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Olopatadine nasal spray vehicle, pH 7.0
Description: Two sprays in each nostril twice a day (morning and evening) for up to 12 months
Study: NCT03226041

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous monitor (TCM-4 monitor)
Description: TCM-4 monitor, which had changed new electrode membrane and was calibrated by the same person(who had been trained systematically) before each placement. The electrode should be heated to 44℃, then fixed it to the anterior part of chest in the location of lateral position after remove grease by alcohol. The positon of electrode must be changed every 2 hours in order to avoid thermal injury, and should be calibrated again.
Study: NCT03612570

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nano-Pulse Stimulation Device
Description: NPS utilizes a timed series of low energy, high voltage nanosecond (billionth of a second) pulses which are applied directly to targeted tissue using small microneedles. NPS energy induces cell signaling and the activation of cellular pathways by creating transient nanopores in cellular membranes and organelles and initiate regulated cell death.
Study: NCT02972307

Intervention type: OTHER
Intervention: wheelchair skills
Description: the extent to which caregivers enhance the wheelchair skills of powered wheelchair users
Study: NCT02145884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: timolol maleate 0.5% gel
Description: Apply timolol gel 1-2 drops twice a day to lesion
Study: NCT02334657

Intervention type: OTHER
Intervention: SF-36
Description: postal questionnaire consisting a short-form health survey with 36 simple questions (SF-36)

Intervention type: OTHER
Intervention: SF-36
Description: postal questionnaire consisting a short-form health survey with 36 simple questions (SF-36)

Intervention type: OTHER
Intervention: SF-36
Description: postal questionnaire consisting a short-form health survey with 36 simple questions (SF-36)

Intervention type: OTHER
Intervention: SF-36
Description: postal questionnaire consisting a short-form health survey with 36 simple questions (SF-36)

Intervention type: OTHER
Intervention: SF-36
Description: postal questionnaire consisting a short-form health survey with 36 simple questions (SF-36)
Study: NCT04821167

Intervention type: PROCEDURE
Group type: OTHER
Intervention: laparoscopic orchiopexy for intra-canalicular testis
Description: laparoscopic orchiolysis of abnormal fibrous attachments and then lap assisted transcrotal fixation of the testis in subdartos pouch for intra-canalicular testis
Study: NCT00767026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COPE (Creating Opportunities for Parent Empowerment)
Description: Twenty-four hours after admission to the hospital, this group will receive Phase I of the study which includes information focusing on what parents can expect during their child's hospital stay, and how they can help their child cope with the experience. Prior to discharge parents will receive additional information pertaining to Phase II of the study. At 3 days post discharge, the participants will receive a follow up phone call to reiterate the information provided in Phase II and ask parents about questions or problems since discharge. One week following, participants will be asked to complete assessments. At 6 weeks after the hospitalization they will receive Phase III, which includes, additional information on behaviors parents can expect to see in their children following a hospitalization. Parents will be given a workbook that will teach them techniques to help their child cope. Then at 6 weeks after the last intervention phase, participants will again complete assessments.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard education
Description: This group will receive standard education regarding medication management and seizure first aid. This group will also receive information, oral and written, that will discuss tests to be administered during the hospitalization. The usual care group also receives a call at home within one week after discharge from a nurse to ask if they had any problems with their stay, and if they have any further needs or questions.
Study: NCT03717753

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pathway
Description: The study team emphasizes that all components of the pathway are considered standard of care at this institution. The objective of this study is to ensure that the study patients assigned to the pathway will receive these standard of care components. Both groups will receive identical postoperative follow-up.
Study: NCT02247128

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin + clopidogrel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin monotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OAC + clopicogrel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OAC monotherapy
Study: NCT04163757

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: crocin
Description: 2 tablets crocin per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 tablets placebo per day
Study: NCT04055012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500mg tabs of Metformin Extended Release
Study: NCT01980940

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo gel applied topically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 50 mg 4% DMSO
Description: Etoricoxib 50 mg 4% DMSO gel applied topically.
Study: NCT04055012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500mg tabs of Metformin Extended Release

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: 500mg tabs of Metformin Extended Release

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Tabs

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo Tabs
Study: NCT03518151

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product placement intervention
Description: The intervention includes 3 components: i) creation of a new fresh fruit and vegetable section and island in the first aisle; ii) placing frozen fruit and vegetables in the first aisle and iii) removal of all cakes, confectionary and sugar sweetened beverages from checkouts (replaced with non-food items, fruit and bottled water).
Study: NCT04483115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN171H
Description: Tablets; Oral; Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN171H
Description: Tablets; Oral; Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN171H
Description: Tablets; Oral; Single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets; Oral; Single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: Tablets; Oral; Single dose
Study: NCT03518151

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham comparator
Description: The control condition is provision of a limited range of fresh fruit and vegetables, all placed at the back of the store, frozen vegetables in a middle aisle and confectionery sold at checkouts.
Study: NCT04089358

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Receive educational materials

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive educational materials
Study: NCT04483115

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: Tablets; Oral; Single dose
Study: NCT04089358

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FitBit
Description: Wear a Fitbit

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FitBit
Description: Wear a Fitbit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goal Setting
Description: Set goals

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Promotion and Education
Description: Receive text message about goal setting

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Media Intervention
Description: Follow Instagram group

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive phone call about goal setting
Study: NCT00829998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zaleplon 10 mg Capsules
Description: 1 x 10 mg, single-dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sonata® 10 mg Capsules
Description: 1 x 10 mg, single-dose fasting
Study: NCT04548011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: The acupuncture treatment strategies in this study are based on traditional Chinese medicine theory and opinions from the acupuncture experts. The acupoints are bilateral Zhongwan（CV12）, Tianshu（ST25）, Neiguan（PC6）, Liangqiu（ST34）, Yanglinquan（GB34）, Zusanli（ST36）and Taichong（LR3）.All the acupoints will be localized according to the Nomenclature and Location of Acupuncture Points of the People's Republic of China. During the acupuncture treatment, the participants will be in supine position. After 75% alcohol pads sterilizing the skin around the acupoints routinely, the acupuncturists will use sterile disposable steel needles (0.3 mm×40 mm; Huatuo Brand, Suzhou Medical Appliance, China) to insert into the acupoints above. The acupoints will be inserted vertically at 13-40 mm with the manipulation of steady small lifting, thrusting, and twirling 3 times to induce a sensation of de qi (sourness, numbness, and heaviness).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: The acupuncture treatment strategies in this study are based on traditional Chinese medicine theory and opinions from the acupuncture experts. The acupoints are bilateral Zhongwan（CV12）, Tianshu（ST25）, Neiguan（PC6）, Liangqiu（ST34）, Yanglinquan（GB34）, Zusanli（ST36）and Taichong（LR3）.All the acupoints will be localized according to the Nomenclature and Location of Acupuncture Points of the People's Republic of China. During the acupuncture treatment, the participants will be in supine position. After 75% alcohol pads sterilizing the skin around the acupoints routinely, the acupuncturists will use sterile disposable steel needles (0.3 mm×40 mm; Huatuo Brand, Suzhou Medical Appliance, China) to insert into the acupoints above. The acupoints will be inserted vertically at 13-40 mm with the manipulation of steady small lifting, thrusting, and twirling 3 times to induce a sensation of de qi (sourness, numbness, and heaviness).
Study: NCT00597350

Intervention type: DIETARY_SUPPLEMENT
Intervention: Trigonella foenum-graecum (fenugreek)
Description: 2 slices of bread containing 5 grams of the natural herb fenugreek 2 times, 1 week apart
Study: NCT01209039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1144814
Description: Multiple daily doses of GSK1144814 for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1144814
Description: Multiple daily doses of GSK1144814 for 14 days
Study: NCT01527994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Aprepitant 125 mg oral tablets
Study: NCT03215706

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified day
Study: NCT01980940

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo to Etoricoxib 50 mg 4% DMSO Gel
Description: Matching Placebo to Etoricoxib 50 mg 4% DMSO gel applied topically.
Study: NCT01423370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHD1023
Description: 5g oral once daily
Study: NCT01527994

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: Placebo oral pill- inactive compound
Study: NCT03048682

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley catheter - Early Voiding Trial
Description: All subjects that are discharged home with a Foley catheter will need an in-office repeat voiding trial.~Subjects in the Early Voiding group will have their repeat voiding trial on post-op day #2, 3, or 4 will undergo an in-office voiding trial. The experimental group will return for an in-office voiding trial sooner than the active comparator.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley catheter - Late Voiding Trial
Description: All subjects that are discharged home with a Foley catheter will need an in-office repeat voiding trial.~Subjects in the Late Voiding group will have their repeat voiding trial on post-op day #7 or after. This is our current practice
Study: NCT01209039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1144814
Description: Multiple daily doses of GSK1144814 for 7 days (or until steady state is reached)
Study: NCT01423370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHD1023
Description: 5g oral twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHD1023
Description: 10g oral once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cialis
Description: 5mg oral once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study: NCT04262570

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multispectral Optoacoustic Tomography (MSOT) and Magnetic Resonance Imaging (MRI)
Description: Non-invasive transcutaneous imaging of molecular muscle components

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multispectral Optoacoustic Tomography (MSOT) and Magnetic Resonance Imaging (MRI)
Description: Non-invasive transcutaneous imaging of molecular muscle components
Study: NCT00600457

Intervention type: DEVICE
Intervention: Polyurethane Film
Description: The modified polyurethane film is combined with a secondary absorbent dressing and remained intact until the 10th postoperative day
Study: NCT01682200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ProOxy
Description: Clean the face with ProOxy facial wash before spraying ProOxy on the face enough to wet it twice daily, upon waking up and before bedtime.
Study: NCT02021760

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary Percutaneous Coronary Intervention
Description: Primary Percutanous Coronary Intervention is performed in both Groups.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Primary Percutaneous Coronary Intervention
Description: Primary Percutanous Coronary Intervention is performed in both Groups.
Study: NCT01477619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasimelteon
Description: 20mg single dose on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasimelteon
Description: 20mg single dose on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasimelteon
Description: 20mg single dose on Day 1
Study: NCT03215706

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Specified dose on specified day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Specified dose on specified day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Specified dose on specified day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Specified dose on specified day
Study: NCT02517411

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: The standard care of stable COPD is based on long-acting bronchodilators (LABD).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy added to standard care
Description: The treatment will be based on domiciliary physiotherapy program during 8 weeks, twice a week added to standard care. The duration of the sessions will be 45-60 minutes. The physiotherapy treatment includes: breathing exercises, electrostimulation in quadriceps with voluntary contraction and exercises with theraband. This will be a home-based program supervised by a physiotherapist.
Study: NCT04092985

Intervention type: DEVICE
Intervention: iECG recording
Description: iECG tracings will be recorded simultaneously, starting and ending at the same time as the standard 12-lead ECG, using the built-in sensors of a smart watch (Apple Watch Series 4) with the ECG application
Study: NCT03215706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Specified dose on specified day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Specified dose on specified day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Specified dose on specified day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Specified dose on specified day
Study: NCT02058927

Intervention type: DRUG
Intervention: Measles vaccine
Description: measles revaccination administered at 12 months from start of ART
Study: NCT02811458

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Cognitive-Behavioral Therapy
Description: Treatment in the Transdiagnostic CBT condition will consist of 12 weekly 2-hour sessions following the manualized treatment protocol including psychoeducation, cognitive restructuring, exposure and relapse prevention.
Study: NCT03699852

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Membracel and LED photobiomodulation
Description: Participants were positioned so that the skin graft donor area was accessible. A light-emitting diode (LED) plate was covered with sterile transparent and waterproof film to prevent contamination when in contact with the donor area. The application was in contact, with full coverage of the surgical wound and was irradiated with radiant exposure of 1.53J / cm2 and irradiance of 2.55 mW / cm2 for 10 minutes. It is worth mentioning that the LED plate was applied in direct contact with the skin graft donor area in the immediate postoperative period and on the primary cover used (Membracel®) on the 1st, 3rd, 5th and 7th postoperative days. Coverage remained until spontaneous departure. The researcher and the participants used specific goggles for this procedure.

Intervention type: OTHER
Group type: OTHER
Intervention: Membracel
Description: This group did not receive LED application, remaining with the skin donor area covered by Membracel® and were evaluated under the same conditions.
Study: NCT00878540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirtazapine
Description: 30 mg mirtazapine once daily for 7 days
Study: NCT00430521

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza vaccine (GSK1119711A)-formulation 1
Description: 2 or 3 doses, intramuscular injection, at different time points.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza vaccine (GSK1119711A)-formulation 1
Description: 2 or 3 doses, intramuscular injection, at different time points.
Study: NCT02652832

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non invasive brain stimulation
Description: non invasive brain stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non invasive brain stimulation
Description: non invasive brain stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: non invasive brain stimulation
Description: non invasive brain stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non invasive brain stimulation
Description: non invasive brain stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non invasive brain stimulation
Description: non invasive brain stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: non invasive brain stimulation
Description: non invasive brain stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: non invasive brain stimulation
Description: non invasive brain stimulation
Study: NCT00430521

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza vaccine (GSK1119711A)-formulation 1
Description: 2 or 3 doses, intramuscular injection, at different time points.
Study: NCT03532191

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PrEP Optimization Intervention (PrEP-OI)
Description: PrEP-Rx + PrEP Coordinator
Study: NCT01212757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 20mg
Description: Apremilast 20 mg twice daily, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 30mg
Description: Apremilast 30 mg twice daily, orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + 20 mg Apremilast
Description: Placebo + 20 mg Apremilast

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + 30 mg Apremilast
Description: Placebo + 30 mg Apremilast
Study: NCT03714750

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DK crush
Description: revascularization of true coronary bifurcation stenosis in DK crush technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reverse TAP
Description: revascularization of true coronary bifurcation stenosis in Reverse TAP technique
Study: NCT01357044

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Extracts of Punica granatum and Alpinia galanga
Description: Tablets, two in the morning and two in the evening

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, two in the morning and two in the evening